Business · 15/10/2012Updated: 10/17/2026 · 1 min read
National Institutes of Health to Evaluate Exclusive License for Therapeutic Agents for Metastatic Breast Cancer and T-cell Lymphoma
Summary
The National Institutes of Health is considering granting an exclusive evaluation option license to Birich Technologies, Inc. for therapeutic agents targeting metastatic breast cancer and T-cell lymphoma, based on inventions described in three U.S. patent applications.